Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
111M
-
Number of holders
-
167
-
Total 13F shares, excl. options
-
110M
-
Shares change
-
+28M
-
Total reported value, excl. options
-
$1.49B
-
Value change
-
+$396M
-
Put/Call ratio
-
0.37
-
Number of buys
-
99
-
Number of sells
-
-67
-
Price
-
$13.59
Significant Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q3 2025
194 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q3 2025.
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) has 167 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 110M shares
of 111M outstanding shares and own 99.04% of the company stock.
Largest 10 shareholders include FMR LLC (11.4M shares), PERCEPTIVE ADVISORS LLC (8.95M shares), BlackRock, Inc. (7.14M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (6.82M shares), TCG Crossover Management, LLC (6.24M shares), VANGUARD GROUP INC (5.27M shares), Saturn V Capital Management LP (4.6M shares), Commodore Capital LP (4.08M shares), First Light Asset Management, LLC (3.36M shares), and Point72 Asset Management, L.P. (2.79M shares).
This table shows the top 167 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.